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INTRODUCTION
Allogeneic stem cell transplantation is an effective meth-
od of treating children with acquired and inborn hemato-
logical diseases. By quantifying the relative amounts of
donor and recipient cells present, it can be determined
whether engraftment has taken place, or if complete (CC)
or mixed (MC) chimerism exists. Complete chimerism
occurs when all of the bone marrow is from the donor,
while mixed chimerism means that recipient cells are al-
so present. In order to monitor chimerism after HSCT,
different techniques can be used: conversion of blood
group, karyotyping, XY-FISH analysis,  and analysis of
RFLPs, VNTRs, and microsatellites (STRs). We used the
multiplex STR polymerase chain reaction as the most
sensitive and sex-independent technique (C o m e a u et
al., 2001; V e l i z a r o v a et al., 2005).
Short tandem repeats (STRs) are sections of highly
repetitive DNA with tandem repeats of very short sequen-
ces (2-8 bp long). Tens of thousands of STR loci have
been mapped in the human genome so far. The length and
number of repeats within the STR vary considerably be-
tween individuals, which makes them highly informative
for identity testing, genetic mapping, and forensic medi-
cine. The availability of unique STR markers allows
highly efficient differentiation of donor and recipient
DNA in mixed samples.  Fluorescent multiplex PCR pro-
vides the ability to analyze more than one marker at a
time, increasing confidence in the relative quantification
of donor and recipient cells in peripheral blood of the pa-
tient (B u n o et al., 2005; K h a n et al., 2004.
MATERIALS AND METHODS
We studied 10 patients after allogeneic sibling donor
transplantation. Peripheral blood samples were taken for
analyses from recipients and donors before transplanta-
tion, but only from recipients after engraftment. Isolation
of DNA from these samples was performed by the salting
out method, and the DNA diluted to less than 2 ng/μl by
quantification of UV absorbance at 260 nm. For PCR, we
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used the STR multiplex system for 16 markers (Power-
Plex 16 Promega) following the manufacturer’s guide-
lines, PCR being carried out in a Perkin Elmer thermocy-
cler with the following protocol: 95°C for 15 min, 60°C
for 1 min, and 70°C for 1,5 min through 10 cycles; then
90°C for 1 min, 60°C for 1 min, and 70°C for 1,5 min
through 22 cycles; followed by 60°C for 30 min and 4°C
soak. Products of PCR were analyzed on an ABI PRISM
310 genetic analyzer. Analyses were performed using
GENESCAN and GENOTYPER software. Quantifica-
tion of the two cell populations was calculated from the
peak areas. 
RESULTS AND DISCUSSION
In this work, we present our results after one year of
following chimerism in a group of 10 patients after allo-
geneic sibling donor HSCT. Our aim was to establish the
protocol for monitoring chimerism in pediatric patients,
determine the optimal interval between two analyses, and
compare the predictivness of mixed chimerism for re-
lapse in different hematological diseases. 
In our group of patients we monitored chimerism
every 30 days in the first six months, then every 60 days
to the end of one year and every 90 days during the sec-
ond year after HSCT (Table 2).
Clinical characteristics of patients are shown in Ta-
ble 1. 
Patient #1, with anemia aplastica, had decreasing
MC. Thirty days after HSCT, 90% chimerism was
achieved, but it declined to 30% on day +196 after HSCT,
as he evolved to MDS and died due to disease progres-
sion (Table 2 ). 
Patients #2, #7, #10, with anemia aplastica, have
achieved stable mixed chimerism so far. Figure 1 shows
the example of MC in patient #2, with a sex-mismatched
transplant on two informative loci: this patient is hetero-
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Table 1. Patients characteristics. AML – acute mieloid leukemia, NHL – non-Hodgkin lymphoma, HSCT – haematopoietic stem cells transplantation,
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zygous for both alleles of the THO1 locus, and the amel-
ogenin locus is detected on both X and Y chromosomes. 
Patient #3, with thalassemia major, retained stable
MC until 196 days after HSCT; levels of donor chimer-
ism then declined to 40% at 230 days after HSCT, when
graft rejection occurred. He is now being prepared for
new HSCT. 
Patients #4, #5, #6, #9, with AML, achieved CC. Pa-
tient #4 had complications (thrombotic microangiopathy
associated with HSCT) and died on day + 84 after HSCT.
Patient #9 died 5 months after HSCT due to relapse. Pa-
tients #5 and #6 have survived for more than one year
now. Figure 2 shows the example of patient #5 before and
after HSCT.
Patient #8, with non-Hodgkin lymphoma, had CC
for three months after HSCT, then died after disease pro-
gression. Decline in levels of donor chimerism was not
observed (Table 2).
In two patients (#1, #3) with non-malignant disor-
ders (anemia aplastica and thalassemia major), we ob-
served MC and could predict a negative outcome, as de-
crease of donor chimerism was detected prior to graft re-
jection. Contrary to this, in one patient (#9) with AML
and one patient (#8) with NHL, we observed CC, but
death occured too quickly for us to intervene appropriate-
ly. We therefore conclude from our results that data ob-
tained in STR-PCR analysis of chimerism correlate with
clinico-hematological findings of remission or relapse of
non-malignant diseases, and this is confirmed in the liter-
ature; however, our results (out of four patients with CC,
two survived and two died) could not confirm the exis-
tence of a strong correlation between remission and hem-
atopoetic CC, which is the most debatable issue in HSCT
(A n t i n et al., 2001).
We conclude that STR analysis by fluorescent mul-
tiplex PCR allows simultaneous genotyping of 16 STR
markers in a single reaction, which renders it highly in-
formative and make possible analysis from a small
amount of extracted DNA (< 2 ng/μl), since there is a lim-
ited  sample source (because patients underwent strong
chemotherapy before HSCT). Its high sensitivity (1-5%)
and reproducibility makes this method extremely valua-
ble for monitoring HSCT (F u n d i a et al., 2004; S e l -
l a t h a m b y et al., 2006). Although STRs are increas-
ingly used for HSCT engraftment analysis, neither guide-
lines nor standards have been established (S c h i c h a -
m a n et al., 2002). Our recommendation for chimerism
analysis is that it be performed at 1, 2, 3, 4, 6, 8, 10, and
12 months after transplantation, and then in the second
year every 6 months or as needed, depending on the dis-
HEMATOPOIETIC STEM CELL TRANSPLANTATION MONITORING USING STR-PCR 25
Fig. 1. Peak tracing for STR PCR analysis for THO1 and Amelogenin
loci in patient #2 with MC.
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ease and clinical findings. If the proportion of donor cells
is observed to decline, ongoing monthly follow-up is
warranted. Interventions to enhance donor engraftment
must be considered on a disease-specific basis and ulti-
mately by clinical rationale (A n t i n et al., 2001).
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Fig. 2. Peak tracing for STR PCR analysis for Amelogenin, FGA and D8S1179 loci in patient #5 with CC.
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Трансплантација матичних ћелија хематопоезе је ме-
дицинска процедура у лечењу оболелих од урођених
или стечених болести. 
Значај праћења химеризма, након транспланта-
ције матичним  ћелијама хематопоезе је да се предви-
де негативни исходи као што су релапс болести или
одбацивање калема, како би могла да се примени
адекватна терапија. Квантификацијом релативног
броја ћелија даваоца и примаоца присутних у узорку
периферне крви примаоца, могуће је одредити да ли
је калем прихваћен, као и да ли је у питању комплет-
ни или мешани химеризам.
У нашој групи од 10 трансплантираних пације-
ната користили смо реакцију ланчаног умножавања
(PCR) кратких тандемских поновака (STRs), имајући
у виду да поседују високу осетљивост и информатив-
ност, те стога представљају оптималну методу избора
за праћење химеризма.
